Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
RESEARCH AND DEVELOPMENT- AOI #16+ SEEKING TO MANUFACTURE AND OBTAIN REGULATORY APPROVAL FOR THE CYTOTRACKER BV, A POINT-OF-CARE INSTANT WHITE BLOOD CELL ANALYSIS PLATFORM FOR DISCRIMINATING BETWEEN ACUTE VIRAL AND BACTERIAL INFECTIONS. is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Rizlab Health Inc. Estimated value $2.5M ($2.5M obligated). Current period of performance ends Apr 10, 2027. Last award drew 1 bidder. Place of performance: PRINCETON NJ. Related solicitation EZ-BAA-22-100-SOL-00003.
RESEARCH AND DEVELOPMENT- AOI #16+ SEEKING TO MANUFACTURE AND OBTAIN REGULATORY APPROVAL FOR THE CYTOTRACKER BV, A POINT-OF-CARE INSTANT WHITE BLOOD CELL ANALYSIS PLATFORM FOR DISCRIMINATING BETWEEN ACUTE VIRAL AND BACTERIAL INFECTIONS.
Recompete timing
PublicCurrent PoP ends Apr 10, 2027 (195 days remaining). Agencies typically plan 12–18 months ahead — at 6.4 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75A50123C00028? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordRizlab Health Inc — $75K obligated across 2 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50123C00028?
75A50123C00028 (Research and development- AOI #16+ seeking) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $2.5M, currently held by Rizlab Health Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50123C00028?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50123C00028 to Rizlab Health Inc (potential $2.5M).
Who is the incumbent on 75A50123C00028?
Rizlab Health Inc is the incumbent with $75K across 2 related awards in SCOUT’s public footprint. The current period of performance ends Apr 10, 2027.
When does Rizlab Health Inc’s 75A50123C00028 come up for recompete?
SCOUT tracks a period-of-performance end of Apr 10, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50123C00028? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.